- Aura Biosciences Inc AURA detailed interim data from its ongoing phase 2 trial of an eye cancer drug, elzupacap sarotalocan (AU-011).
- Belzupacap sarotalocan controlled tumors in most patients over longer courses of treatment. Nearly all patients retained their vision in an interim view of the Phase 2 study with a data cut-off dated August 19 at the American Academy of Ophthalmology conference in the second city.
- Two of the nine patients received 40 μg and the other seven received 80 μg. According to that presentationone subject in the cohort was not included in the analysis because he discontinued treatment after one cycle for unrelated serious adverse events.
- Related: JMP is bullish on this cancer stock “sees new way to treat cancer.”
- Results demonstrated a statistically significant reduction in tumor growth rate compared to each patient’s documented growth rate at study entry and a tumor control rate of 88.9% (8/9).
- The tumor control rate was less evident in the groups without three treatment cycles. In the lower dose and less frequent drug dose groups, tumors were under control in only two out of nine patients, as observed at a median follow-up of 11 months.
- The patient, who received two cycles of the drug at 40 μg, saw no tumor control after six months of follow-up.
- In addition, the visual acuity preservation rate was 88.9%, with most patients at high risk of vision loss with tumors near the fovea or the optic disc.
- The overall safety profile of belzupacap sarotalocan was generally favorable, with no dose-limiting toxicities or treatment-emergent side effects.
- Price promotion: AURA shares are down 16.8% to $15.08 on the latest check Monday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
